 | • レポートコード：MRC2-11QY07955 • 出版社/出版日：QYResearch / 2020年11月20日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療、製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥865,800 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料は筋緊張性ジストロフィー治療薬のグローバル市場について調査・分析したレポートです。種類別（ISIS-DMPKRx、PRO-135、SRT-152、VAL-0411、その他）市場規模、用途別（病院、診療所、家庭、その他）市場規模、地域別（北米、米国、カナダ、ヨーロッパ、ドイツ、フランス、イギリス、イタリア、ロシア、アジア、日本、中国、韓国、インド、オーストラリア、台湾、中南米、メキシコ、ブラジル、アルゼンチン、中東・アフリカ、トルコ、サウジアラビア、UAE等）市場規模データ、主な企業情報と企業別市場シェア等が収録されています。 ・調査範囲 ・エグゼクティブサマリー ・企業別筋緊張性ジストロフィー治療薬の競争状況、市場シェア ・世界の筋緊張性ジストロフィー治療薬市場：種類別市場規模 2015年-2020年（ISIS-DMPKRx、PRO-135、SRT-152、VAL-0411、その他） ・世界の筋緊張性ジストロフィー治療薬市場：種類別市場規模予測 2021年-2026年（ISIS-DMPKRx、PRO-135、SRT-152、VAL-0411、その他） ・世界の筋緊張性ジストロフィー治療薬市場：用途別市場規模 2015年-2020年（病院、診療所、家庭、その他） ・世界の筋緊張性ジストロフィー治療薬市場：用途別市場規模予測 2021年-2026年（病院、診療所、家庭、その他） ・北米の筋緊張性ジストロフィー治療薬市場分析：米国、カナダ ・ヨーロッパの筋緊張性ジストロフィー治療薬市場分析：ドイツ、フランス、イギリス、イタリア、ロシア等 ・アジアの筋緊張性ジストロフィー治療薬市場分析：日本、中国、韓国、インド、オーストラリア、台湾等 ・中南米の筋緊張性ジストロフィー治療薬市場分析：メキシコ、ブラジル、アルゼンチン等 ・中東・アフリカの筋緊張性ジストロフィー治療薬市場分析：トルコ、サウジアラビア、UAE等 ・企業情報（企業概要、製品概要、販売量、企業動向） - 掲載企業（変更可能性あり）：BioMarin Pharmaceutical Inc.、F. Hoffmann-La Roche Ltd.、Genzyme Corporation、Isis Pharmaceuticals, Inc.、Marina Biotech, Inc.、Valentia Biopharma S.L. ・地域別市場規模予測（2021年-2026年）：北米市場、ヨーロッパ市場、アジア市場、中南米市場、中東・アフリカ市場 ・市場機会、課題、リスク、環境分析 ・バリューチェーン、販売チャネル分析 ・調査の結論 |
Market Analysis and Insights: Global Myotonic Dystrophy Drug Market
The global Myotonic Dystrophy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026.
Global Myotonic Dystrophy Drug Scope and Market Size
Myotonic Dystrophy Drug market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Myotonic Dystrophy Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2015-2026.
Segment by Type, the Myotonic Dystrophy Drug market is segmented into
ISIS-DMPKRx
PRO-135
SRT-152
VAL-0411
Others
Segment by Application, the Myotonic Dystrophy Drug market is segmented into
Hospital
Clinic
Home Use
Others
Regional and Country-level Analysis
The Myotonic Dystrophy Drug market is analysed and market size information is provided by regions (countries).
The key regions covered in the Myotonic Dystrophy Drug market report are North America, Europe, Asia Pacific, Latin America, Middle East and Africa. It also covers key regions (countries), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.
The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of sales and revenue for the period 2015-2026.
Competitive Landscape and Myotonic Dystrophy Drug Market Share Analysis
Myotonic Dystrophy Drug market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Myotonic Dystrophy Drug business, the date to enter into the Myotonic Dystrophy Drug market, Myotonic Dystrophy Drug product introduction, recent developments, etc.
The major vendors covered:
BioMarin Pharmaceutical Inc.
F. Hoffmann-La Roche Ltd.
Genzyme Corporation
Isis Pharmaceuticals, Inc.
Marina Biotech, Inc.
Valentia Biopharma S.L.
…
1 Study Coverage
1.1 Myotonic Dystrophy Drug Product Introduction
1.2 Market Segments
1.3 Key Myotonic Dystrophy Drug Manufacturers Covered: Ranking by Revenue
1.4 Market by Type
1.4.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Type
1.4.2 ISIS-DMPKRx
1.4.3 PRO-135
1.4.4 SRT-152
1.4.5 VAL-0411
1.4.6 Others
1.5 Market by Application
1.5.1 Global Myotonic Dystrophy Drug Market Size Growth Rate by Application
1.5.2 Hospital
1.5.3 Clinic
1.5.4 Home Use
1.5.5 Others
1.6 Study Objectives
1.7 Years Considered
2 Executive Summary
2.1 Global Myotonic Dystrophy Drug Market Size, Estimates and Forecasts
2.1.1 Global Myotonic Dystrophy Drug Revenue 2015-2026
2.1.2 Global Myotonic Dystrophy Drug Sales 2015-2026
2.2 Global Myotonic Dystrophy Drug, Market Size by Producing Regions: 2015 VS 2020 VS 2026
2.2.1 Global Myotonic Dystrophy Drug Retrospective Market Scenario in Sales by Region: 2015-2020
2.2.2 Global Myotonic Dystrophy Drug Retrospective Market Scenario in Revenue by Region: 2015-2020
3 Global Myotonic Dystrophy Drug Competitor Landscape by Players
3.1 Myotonic Dystrophy Drug Sales by Manufacturers
3.1.1 Myotonic Dystrophy Drug Sales by Manufacturers (2015-2020)
3.1.2 Myotonic Dystrophy Drug Sales Market Share by Manufacturers (2015-2020)
3.2 Myotonic Dystrophy Drug Revenue by Manufacturers
3.2.1 Myotonic Dystrophy Drug Revenue by Manufacturers (2015-2020)
3.2.2 Myotonic Dystrophy Drug Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Myotonic Dystrophy Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)
3.2.4 Global Top 10 and Top 5 Companies by Myotonic Dystrophy Drug Revenue in 2019
3.2.5 Global Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Myotonic Dystrophy Drug Price by Manufacturers
3.4 Myotonic Dystrophy Drug Manufacturing Base Distribution, Product Types
3.4.1 Myotonic Dystrophy Drug Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Myotonic Dystrophy Drug Product Type
3.4.3 Date of International Manufacturers Enter into Myotonic Dystrophy Drug Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Myotonic Dystrophy Drug Market Size by Type (2015-2020)
4.1.1 Global Myotonic Dystrophy Drug Sales by Type (2015-2020)
4.1.2 Global Myotonic Dystrophy Drug Revenue by Type (2015-2020)
4.1.3 Myotonic Dystrophy Drug Average Selling Price (ASP) by Type (2015-2026)
4.2 Global Myotonic Dystrophy Drug Market Size Forecast by Type (2021-2026)
4.2.1 Global Myotonic Dystrophy Drug Sales Forecast by Type (2021-2026)
4.2.2 Global Myotonic Dystrophy Drug Revenue Forecast by Type (2021-2026)
4.2.3 Myotonic Dystrophy Drug Average Selling Price (ASP) Forecast by Type (2021-2026)
4.3 Global Myotonic Dystrophy Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Market Size by Application (2015-2026)
5.1 Global Myotonic Dystrophy Drug Market Size by Application (2015-2020)
5.1.1 Global Myotonic Dystrophy Drug Sales by Application (2015-2020)
5.1.2 Global Myotonic Dystrophy Drug Revenue by Application (2015-2020)
5.1.3 Myotonic Dystrophy Drug Price by Application (2015-2020)
5.2 Myotonic Dystrophy Drug Market Size Forecast by Application (2021-2026)
5.2.1 Global Myotonic Dystrophy Drug Sales Forecast by Application (2021-2026)
5.2.2 Global Myotonic Dystrophy Drug Revenue Forecast by Application (2021-2026)
5.2.3 Global Myotonic Dystrophy Drug Price Forecast by Application (2021-2026)
6 North America
6.1 North America Myotonic Dystrophy Drug by Country
6.1.1 North America Myotonic Dystrophy Drug Sales by Country
6.1.2 North America Myotonic Dystrophy Drug Revenue by Country
6.1.3 U.S.
6.1.4 Canada
6.2 North America Myotonic Dystrophy Drug Market Facts & Figures by Type
6.3 North America Myotonic Dystrophy Drug Market Facts & Figures by Application
7 Europe
7.1 Europe Myotonic Dystrophy Drug by Country
7.1.1 Europe Myotonic Dystrophy Drug Sales by Country
7.1.2 Europe Myotonic Dystrophy Drug Revenue by Country
7.1.3 Germany
7.1.4 France
7.1.5 U.K.
7.1.6 Italy
7.1.7 Russia
7.2 Europe Myotonic Dystrophy Drug Market Facts & Figures by Type
7.3 Europe Myotonic Dystrophy Drug Market Facts & Figures by Application
8 Asia Pacific
8.1 Asia Pacific Myotonic Dystrophy Drug by Region
8.1.1 Asia Pacific Myotonic Dystrophy Drug Sales by Region
8.1.2 Asia Pacific Myotonic Dystrophy Drug Revenue by Region
8.1.3 China
8.1.4 Japan
8.1.5 South Korea
8.1.6 India
8.1.7 Australia
8.1.8 Taiwan
8.1.9 Indonesia
8.1.10 Thailand
8.1.11 Malaysia
8.1.12 Philippines
8.1.13 Vietnam
8.2 Asia Pacific Myotonic Dystrophy Drug Market Facts & Figures by Type
8.3 Asia Pacific Myotonic Dystrophy Drug Market Facts & Figures by Application
9 Latin America
9.1 Latin America Myotonic Dystrophy Drug by Country
9.1.1 Latin America Myotonic Dystrophy Drug Sales by Country
9.1.2 Latin America Myotonic Dystrophy Drug Revenue by Country
9.1.3 Mexico
9.1.4 Brazil
9.1.5 Argentina
9.2 Central & South America Myotonic Dystrophy Drug Market Facts & Figures by Type
9.3 Central & South America Myotonic Dystrophy Drug Market Facts & Figures by Application
10 Middle East and Africa
10.1 Middle East and Africa Myotonic Dystrophy Drug by Country
10.1.1 Middle East and Africa Myotonic Dystrophy Drug Sales by Country
10.1.2 Middle East and Africa Myotonic Dystrophy Drug Revenue by Country
10.1.3 Turkey
10.1.4 Saudi Arabia
10.1.5 U.A.E
10.2 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Type
10.3 Middle East and Africa Myotonic Dystrophy Drug Market Facts & Figures by Application
11 Company Profiles
11.1 BioMarin Pharmaceutical Inc.
11.1.1 BioMarin Pharmaceutical Inc. Corporation Information
11.1.2 BioMarin Pharmaceutical Inc. Description and Business Overview
11.1.3 BioMarin Pharmaceutical Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Products Offered
11.1.5 BioMarin Pharmaceutical Inc. Related Developments
11.2 F. Hoffmann-La Roche Ltd.
11.2.1 F. Hoffmann-La Roche Ltd. Corporation Information
11.2.2 F. Hoffmann-La Roche Ltd. Description and Business Overview
11.2.3 F. Hoffmann-La Roche Ltd. Sales, Revenue and Gross Margin (2015-2020)
11.2.4 F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Products Offered
11.2.5 F. Hoffmann-La Roche Ltd. Related Developments
11.3 Genzyme Corporation
11.3.1 Genzyme Corporation Corporation Information
11.3.2 Genzyme Corporation Description and Business Overview
11.3.3 Genzyme Corporation Sales, Revenue and Gross Margin (2015-2020)
11.3.4 Genzyme Corporation Myotonic Dystrophy Drug Products Offered
11.3.5 Genzyme Corporation Related Developments
11.4 Isis Pharmaceuticals, Inc.
11.4.1 Isis Pharmaceuticals, Inc. Corporation Information
11.4.2 Isis Pharmaceuticals, Inc. Description and Business Overview
11.4.3 Isis Pharmaceuticals, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.4.4 Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Products Offered
11.4.5 Isis Pharmaceuticals, Inc. Related Developments
11.5 Marina Biotech, Inc.
11.5.1 Marina Biotech, Inc. Corporation Information
11.5.2 Marina Biotech, Inc. Description and Business Overview
11.5.3 Marina Biotech, Inc. Sales, Revenue and Gross Margin (2015-2020)
11.5.4 Marina Biotech, Inc. Myotonic Dystrophy Drug Products Offered
11.5.5 Marina Biotech, Inc. Related Developments
11.6 Valentia Biopharma S.L.
11.6.1 Valentia Biopharma S.L. Corporation Information
11.6.2 Valentia Biopharma S.L. Description and Business Overview
11.6.3 Valentia Biopharma S.L. Sales, Revenue and Gross Margin (2015-2020)
11.6.4 Valentia Biopharma S.L. Myotonic Dystrophy Drug Products Offered
11.6.5 Valentia Biopharma S.L. Related Developments
11.1 BioMarin Pharmaceutical Inc.
11.1.1 BioMarin Pharmaceutical Inc. Corporation Information
11.1.2 BioMarin Pharmaceutical Inc. Description and Business Overview
11.1.3 BioMarin Pharmaceutical Inc. Sales, Revenue and Gross Margin (2015-2020)
11.1.4 BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Products Offered
11.1.5 BioMarin Pharmaceutical Inc. Related Developments
12 Future Forecast by Regions (Countries) (2021-2026)
12.1 Myotonic Dystrophy Drug Market Estimates and Projections by Region
12.1.1 Global Myotonic Dystrophy Drug Sales Forecast by Regions 2021-2026
12.1.2 Global Myotonic Dystrophy Drug Revenue Forecast by Regions 2021-2026
12.2 North America Myotonic Dystrophy Drug Market Size Forecast (2021-2026)
12.2.1 North America: Myotonic Dystrophy Drug Sales Forecast (2021-2026)
12.2.2 North America: Myotonic Dystrophy Drug Revenue Forecast (2021-2026)
12.2.3 North America: Myotonic Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.3 Europe Myotonic Dystrophy Drug Market Size Forecast (2021-2026)
12.3.1 Europe: Myotonic Dystrophy Drug Sales Forecast (2021-2026)
12.3.2 Europe: Myotonic Dystrophy Drug Revenue Forecast (2021-2026)
12.3.3 Europe: Myotonic Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.4 Asia Pacific Myotonic Dystrophy Drug Market Size Forecast (2021-2026)
12.4.1 Asia Pacific: Myotonic Dystrophy Drug Sales Forecast (2021-2026)
12.4.2 Asia Pacific: Myotonic Dystrophy Drug Revenue Forecast (2021-2026)
12.4.3 Asia Pacific: Myotonic Dystrophy Drug Market Size Forecast by Region (2021-2026)
12.5 Latin America Myotonic Dystrophy Drug Market Size Forecast (2021-2026)
12.5.1 Latin America: Myotonic Dystrophy Drug Sales Forecast (2021-2026)
12.5.2 Latin America: Myotonic Dystrophy Drug Revenue Forecast (2021-2026)
12.5.3 Latin America: Myotonic Dystrophy Drug Market Size Forecast by Country (2021-2026)
12.6 Middle East and Africa Myotonic Dystrophy Drug Market Size Forecast (2021-2026)
12.6.1 Middle East and Africa: Myotonic Dystrophy Drug Sales Forecast (2021-2026)
12.6.2 Middle East and Africa: Myotonic Dystrophy Drug Revenue Forecast (2021-2026)
12.6.3 Middle East and Africa: Myotonic Dystrophy Drug Market Size Forecast by Country (2021-2026)
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Market Opportunities and Drivers
13.2 Market Challenges
13.3 Market Risks/Restraints
13.4 Porter’s Five Forces Analysis
13.5 Primary Interviews with Key Myotonic Dystrophy Drug Players (Opinion Leaders)
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Myotonic Dystrophy Drug Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Myotonic Dystrophy Drug Market Segments
Table 2. Ranking of Global Top Myotonic Dystrophy Drug Manufacturers by Revenue (US$ Million) in 2019
Table 3. Global Myotonic Dystrophy Drug Market Size Growth Rate by Type 2020-2026 (K Pcs) & (US$ Million)
Table 4. Major Manufacturers of ISIS-DMPKRx
Table 5. Major Manufacturers of PRO-135
Table 6. Major Manufacturers of SRT-152
Table 7. Major Manufacturers of VAL-0411
Table 8. Major Manufacturers of Others
Table 9. Global Myotonic Dystrophy Drug Market Size Growth Rate by Application 2020-2026 (K Pcs)
Table 10. Global Myotonic Dystrophy Drug Market Size by Region (K Pcs) & (US$ Million): 2020 VS 2026
Table 11. Global Myotonic Dystrophy Drug Sales by Regions 2015-2020 (K Pcs)
Table 12. Global Myotonic Dystrophy Drug Sales Market Share by Regions (2015-2020)
Table 13. Global Myotonic Dystrophy Drug Revenue by Regions 2015-2020 (US$ Million)
Table 14. Global Myotonic Dystrophy Drug Sales by Manufacturers (2015-2020) (K Pcs)
Table 15. Global Myotonic Dystrophy Drug Sales Share by Manufacturers (2015-2020)
Table 16. Global Myotonic Dystrophy Drug Manufacturers Market Concentration Ratio (CR5 and HHI) (2015-2020)
Table 17. Global Myotonic Dystrophy Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Myotonic Dystrophy Drug as of 2019)
Table 18. Myotonic Dystrophy Drug Revenue by Manufacturers (2015-2020) (US$ Million)
Table 19. Myotonic Dystrophy Drug Revenue Share by Manufacturers (2015-2020)
Table 20. Key Manufacturers Myotonic Dystrophy Drug Price (2015-2020) (USD/Pcs)
Table 21. Myotonic Dystrophy Drug Manufacturers Manufacturing Base Distribution and Headquarters
Table 22. Manufacturers Myotonic Dystrophy Drug Product Type
Table 23. Date of International Manufacturers Enter into Myotonic Dystrophy Drug Market
Table 24. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 25. Global Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 26. Global Myotonic Dystrophy Drug Sales Share by Type (2015-2020)
Table 27. Global Myotonic Dystrophy Drug Revenue by Type (2015-2020) (US$ Million)
Table 28. Global Myotonic Dystrophy Drug Revenue Share by Type (2015-2020)
Table 29. Myotonic Dystrophy Drug Average Selling Price (ASP) by Type 2015-2020 (USD/Pcs)
Table 30. Global Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 31. Global Myotonic Dystrophy Drug Sales Share by Application (2015-2020)
Table 32. North America Myotonic Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 33. North America Myotonic Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 34. North America Myotonic Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 35. North America Myotonic Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 36. North America Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 37. North America Myotonic Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 38. North America Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 39. North America Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 40. Europe Myotonic Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 41. Europe Myotonic Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 42. Europe Myotonic Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 43. Europe Myotonic Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 44. Europe Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 45. Europe Myotonic Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 46. Europe Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 47. Europe Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 48. Asia Pacific Myotonic Dystrophy Drug Sales by Region (2015-2020) (K Pcs)
Table 49. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Region (2015-2020)
Table 50. Asia Pacific Myotonic Dystrophy Drug Revenue by Region (2015-2020) (US$ Million)
Table 51. Asia Pacific Myotonic Dystrophy Drug Revenue Market Share by Region (2015-2020)
Table 52. Asia Pacific Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 53. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 54. Asia Pacific Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 55. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 56. Latin America Myotonic Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 57. Latin America Myotonic Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 58. Latin Americaa Myotonic Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 59. Latin America Myotonic Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 60. Latin America Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 61. Latin America Myotonic Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 62. Latin America Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 63. Latin America Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 64. Middle East and Africa Myotonic Dystrophy Drug Sales by Country (2015-2020) (K Pcs)
Table 65. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Country (2015-2020)
Table 66. Middle East and Africa Myotonic Dystrophy Drug Revenue by Country (2015-2020) (US$ Million)
Table 67. Middle East and Africa Myotonic Dystrophy Drug Revenue Market Share by Country (2015-2020)
Table 68. Middle East and Africa Myotonic Dystrophy Drug Sales by Type (2015-2020) (K Pcs)
Table 69. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Type (2015-2020)
Table 70. Middle East and Africa Myotonic Dystrophy Drug Sales by Application (2015-2020) (K Pcs)
Table 71. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
Table 72. BioMarin Pharmaceutical Inc. Corporation Information
Table 73. BioMarin Pharmaceutical Inc. Description and Major Businesses
Table 74. BioMarin Pharmaceutical Inc. Myotonic Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 75. BioMarin Pharmaceutical Inc. Product
Table 76. BioMarin Pharmaceutical Inc. Recent Development
Table 77. F. Hoffmann-La Roche Ltd. Corporation Information
Table 78. F. Hoffmann-La Roche Ltd. Description and Major Businesses
Table 79. F. Hoffmann-La Roche Ltd. Myotonic Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 80. F. Hoffmann-La Roche Ltd. Product
Table 81. F. Hoffmann-La Roche Ltd. Recent Development
Table 82. Genzyme Corporation Corporation Information
Table 83. Genzyme Corporation Description and Major Businesses
Table 84. Genzyme Corporation Myotonic Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 85. Genzyme Corporation Product
Table 86. Genzyme Corporation Recent Development
Table 87. Isis Pharmaceuticals, Inc. Corporation Information
Table 88. Isis Pharmaceuticals, Inc. Description and Major Businesses
Table 89. Isis Pharmaceuticals, Inc. Myotonic Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 90. Isis Pharmaceuticals, Inc. Product
Table 91. Isis Pharmaceuticals, Inc. Recent Development
Table 92. Marina Biotech, Inc. Corporation Information
Table 93. Marina Biotech, Inc. Description and Major Businesses
Table 94. Marina Biotech, Inc. Myotonic Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 95. Marina Biotech, Inc. Product
Table 96. Marina Biotech, Inc. Recent Development
Table 97. Valentia Biopharma S.L. Corporation Information
Table 98. Valentia Biopharma S.L. Description and Major Businesses
Table 99. Valentia Biopharma S.L. Myotonic Dystrophy Drug Production (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2015-2020)
Table 100. Valentia Biopharma S.L. Product
Table 101. Valentia Biopharma S.L. Recent Development
Table 102. Global Myotonic Dystrophy Drug Sales Forecast by Regions (2021-2026) (K Pcs)
Table 103. Global Myotonic Dystrophy Drug Sales Market Share Forecast by Regions (2021-2026)
Table 104. Global Myotonic Dystrophy Drug Revenue Forecast by Regions (2021-2026) (US$ Million)
Table 105. Global Myotonic Dystrophy Drug Revenue Market Share Forecast by Regions (2021-2026)
Table 106. North America: Myotonic Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 107. North America: Myotonic Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 108. Europe: Myotonic Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 109. Europe: Myotonic Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 110. Asia Pacific: Myotonic Dystrophy Drug Sales Forecast by Region (2021-2026) (K Pcs)
Table 111. Asia Pacific: Myotonic Dystrophy Drug Revenue Forecast by Region (2021-2026) (US$ Million)
Table 112. Latin America: Myotonic Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 113. Latin America: Myotonic Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 114. Middle East and Africa: Myotonic Dystrophy Drug Sales Forecast by Country (2021-2026) (K Pcs)
Table 115. Middle East and Africa: Myotonic Dystrophy Drug Revenue Forecast by Country (2021-2026) (US$ Million)
Table 116. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 117. Key Challenges
Table 118. Market Risks
Table 119. Main Points Interviewed from Key Myotonic Dystrophy Drug Players
Table 120. Myotonic Dystrophy Drug Customers List
Table 121. Myotonic Dystrophy Drug Distributors List
Table 122. Research Programs/Design for This Report
Table 123. Key Data Information from Secondary Sources
Table 124. Key Data Information from Primary Sources
List of Figures
Figure 1. Myotonic Dystrophy Drug Product Picture
Figure 2. Global Myotonic Dystrophy Drug Sales Market Share by Type in 2020 & 2026
Figure 3. ISIS-DMPKRx Product Picture
Figure 4. PRO-135 Product Picture
Figure 5. SRT-152 Product Picture
Figure 6. VAL-0411 Product Picture
Figure 7. Others Product Picture
Figure 8. Global Myotonic Dystrophy Drug Sales Market Share by Application in 2020 & 2026
Figure 9. Hospital
Figure 10. Clinic
Figure 11. Home Use
Figure 12. Others
Figure 13. Myotonic Dystrophy Drug Report Years Considered
Figure 14. Global Myotonic Dystrophy Drug Market Size 2015-2026 (US$ Million)
Figure 15. Global Myotonic Dystrophy Drug Sales 2015-2026 (K Pcs)
Figure 16. Global Myotonic Dystrophy Drug Market Size Market Share by Region: 2020 Versus 2026
Figure 17. Global Myotonic Dystrophy Drug Sales Market Share by Region (2015-2020)
Figure 18. Global Myotonic Dystrophy Drug Sales Market Share by Region in 2019
Figure 19. Global Myotonic Dystrophy Drug Revenue Market Share by Region (2015-2020)
Figure 20. Global Myotonic Dystrophy Drug Revenue Market Share by Region in 2019
Figure 21. Global Myotonic Dystrophy Drug Sales Share by Manufacturer in 2019
Figure 22. The Top 10 and 5 Players Market Share by Myotonic Dystrophy Drug Revenue in 2019
Figure 23. Myotonic Dystrophy Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 24. Global Myotonic Dystrophy Drug Sales Market Share by Type (2015-2020)
Figure 25. Global Myotonic Dystrophy Drug Sales Market Share by Type in 2019
Figure 26. Global Myotonic Dystrophy Drug Revenue Market Share by Type (2015-2020)
Figure 27. Global Myotonic Dystrophy Drug Revenue Market Share by Type in 2019
Figure 28. Global Myotonic Dystrophy Drug Market Share by Price Range (2015-2020)
Figure 29. Global Myotonic Dystrophy Drug Sales Market Share by Application (2015-2020)
Figure 30. Global Myotonic Dystrophy Drug Sales Market Share by Application in 2019
Figure 31. Global Myotonic Dystrophy Drug Revenue Market Share by Application (2015-2020)
Figure 32. Global Myotonic Dystrophy Drug Revenue Market Share by Application in 2019
Figure 33. North America Myotonic Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 34. North America Myotonic Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 35. North America Myotonic Dystrophy Drug Sales Market Share by Country in 2019
Figure 36. North America Myotonic Dystrophy Drug Revenue Market Share by Country in 2019
Figure 37. U.S. Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 38. U.S. Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Canada Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 40. Canada Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. North America Myotonic Dystrophy Drug Market Share by Type in 2019
Figure 42. North America Myotonic Dystrophy Drug Market Share by Application in 2019
Figure 43. Europe Myotonic Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 44. Europe Myotonic Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 45. Europe Myotonic Dystrophy Drug Sales Market Share by Country in 2019
Figure 46. Europe Myotonic Dystrophy Drug Revenue Market Share by Country in 2019
Figure 47. Germany Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 48. Germany Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. France Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 50. France Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. U.K. Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 52. U.K. Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Italy Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 54. Italy Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Russia Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 56. Russia Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Europe Myotonic Dystrophy Drug Market Share by Type in 2019
Figure 58. Europe Myotonic Dystrophy Drug Market Share by Application in 2019
Figure 59. Asia Pacific Myotonic Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 60. Asia Pacific Myotonic Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 61. Asia Pacific Myotonic Dystrophy Drug Sales Market Share by Region in 2019
Figure 62. Asia Pacific Myotonic Dystrophy Drug Revenue Market Share by Region in 2019
Figure 63. China Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 64. China Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Japan Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 66. Japan Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 67. South Korea Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 68. South Korea Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. India Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 70. India Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Australia Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 72. Australia Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Taiwan Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 74. Taiwan Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 75. Indonesia Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 76. Indonesia Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Thailand Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 78. Thailand Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. Malaysia Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 80. Malaysia Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Philippines Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 82. Philippines Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 83. Vietnam Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 84. Vietnam Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 85. Asia Pacific Myotonic Dystrophy Drug Market Share by Type in 2019
Figure 86. Asia Pacific Myotonic Dystrophy Drug Market Share by Application in 2019
Figure 87. Latin America Myotonic Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 88. Latin America Myotonic Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 89. Latin America Myotonic Dystrophy Drug Sales Market Share by Country in 2019
Figure 90. Latin America Myotonic Dystrophy Drug Revenue Market Share by Country in 2019
Figure 91. Mexico Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 92. Mexico Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 93. Brazil Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 94. Brazil Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 95. Argentina Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 96. Argentina Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 97. Latin America Myotonic Dystrophy Drug Market Share by Type in 2019
Figure 98. Latin America Myotonic Dystrophy Drug Market Share by Application in 2019
Figure 99. Middle East and Africa Myotonic Dystrophy Drug Sales Growth Rate 2015-2020 (K Pcs)
Figure 100. Middle East and Africa Myotonic Dystrophy Drug Revenue Growth Rate 2015-2020 (US$ Million)
Figure 101. Middle East and Africa Myotonic Dystrophy Drug Sales Market Share by Country in 2019
Figure 102. Middle East and Africa Myotonic Dystrophy Drug Revenue Market Share by Country in 2019
Figure 103. Turkey Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 104. Turkey Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 105. Saudi Arabia Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 106. Saudi Arabia Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 107. U.A.E Myotonic Dystrophy Drug Sales Growth Rate (2015-2020) (K Pcs)
Figure 108. U.A.E Myotonic Dystrophy Drug Revenue Growth Rate (2015-2020) (US$ Million)
Figure 109. Middle East and Africa Myotonic Dystrophy Drug Market Share by Type in 2019
Figure 110. Middle East and Africa Myotonic Dystrophy Drug Market Share by Application in 2019
Figure 111. North America Myotonic Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 112. North America Myotonic Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 113. Europe Myotonic Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 114. Europe Myotonic Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 115. Asia Pacific Myotonic Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 116. Asia Pacific Myotonic Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 117. Latin America Myotonic Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 118. Latin America Myotonic Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 119. Middle East and Africa Myotonic Dystrophy Drug Sales Growth Rate Forecast (2021-2026) (K Pcs)
Figure 120. Middle East and Africa Myotonic Dystrophy Drug Revenue Growth Rate Forecast (2021-2026) (US$ Million)
Figure 121. Porter's Five Forces Analysis
Figure 122. Channels of Distribution
Figure 123. Distributors Profiles
Figure 124. Bottom-up and Top-down Approaches for This Report
Figure 125. Data Triangulation
Figure 126. Key Executives Interviewed
ベッカー型筋ジストロフィー治療薬の世界市場（～2026年） Market Analysis and Insights: Global Becker Muscular Dystrophy Drug Market The global Becker Muscular Dystrophy Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Becker Muscular Dystrophy Drug Scope and Market Size …- デュシェンヌ型筋ジストロフィー薬の世界市場（～2026年） Duchenne muscular dystrophy is an X-linked disease, which generally affects the male population. It is characterized by progressive muscle degeneration and weakness. The disease is caused due to mutations in the dystrophin gene, which result in the lack of production of dystrophin (a protein essenti…
- 遺伝性疾患薬の世界市場（～2026年） Market Analysis and Insights: Global Genetic Disorders Drug Market The global Genetic Disorders Drug market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX%% during 2021-2026. Global Genetic Disorders Drug Scope and Market Size Genetic Disorders Drug m…
- 小売薬の世界市場（～2026年） A drug is any substance (other than food that provides nutritional support) that, when inhaled, injected, smoked, consumed, absorbed via a patch on the skin, or dissolved under the tongue causes a temporary physiological (and often psychological) change in the body. Increasing industry share of Asia…
- 家庭用乱用薬物検査の世界市場（～2026年） The at-home DOA testing market has been categorized into rapid DOA test kits and breath analyzers. The market is mainly driven by the increased production and trade of illicit drugs worldwide, growing use of illicit drugs amongst teenagers, and initiatives by government organizations to reduce the l…